Absci Corporation | Small-cap | Healthcare
$2.76
-1.78%
| Absci Stock Comparison:
Absci vs VertexAbsci vs RegeneronAbsci vs Vera TherapeuticsAbsci vs Immunocore HoldingsAbsci vs AgiosAbsci vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 4.5M
Operating Income -108.9M -2,401.59%
Net Income -103.1M -2,274.06%

Balance Sheet Metrics

Total Assets 213.6M
Total Liabilities 34.5M
Shareholders Equity 179.1M
Debt to Equity 0.19

Cash Flow Metrics

Operating Cash Flow -67.9M
Free Cash Flow -72.8M

Revenue & Profitability Trend

Absci Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 4.5M 5.7M 5.7M 4.8M 4.8M
Cost of Goods Sold - - - - -
Gross Profit - - - - -
Operating Expenses 100.0M 85.9M 99.5M 73.4M 17.0M
Operating Income -108.9M -94.2M -106.8M -75.2M -13.3M
Pre-tax Income -103.0M -110.5M -105.4M -109.9M -14.4M
Income Tax 70.0K 100.0K -461.0K -8.9M 0
Net Income -103.1M -110.6M -104.9M -101.0M -14.4M
EPS (Diluted) - -$1.20 -$1.15 -$2.08 -$0.55

Income Statement Trend

Absci Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 133.8M 120.6M 186.9M 273.1M 73.2M
Non-Current Assets 79.8M 96.7M 134.1M 153.1M 15.3M
Total Assets 213.6M 217.3M 321.0M 426.2M 88.6M
Liabilities
Current Liabilities 28.7M 29.6M 30.3M 33.9M 10.1M
Non-Current Liabilities 5.8M 11.6M 16.3M 26.2M 167.9M
Total Liabilities 34.5M 41.1M 46.6M 60.1M 178.0M
Equity
Total Shareholders Equity 179.1M 176.2M 274.4M 366.1M -89.4M

Balance Sheet Composition

Absci Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -103.1M -110.6M -104.9M -101.0M -14.4M
Operating Cash Flow -67.9M -83.7M -81.3M -57.7M -11.4M
Investing Activities
Capital Expenditures 535.0K -606.0K -16.0M -38.0M -2.2M
Investing Cash Flow -41.6M 81.9M -127.0M -67.4M -2.2M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow 82.5M -4.5M 5.2M 336.2M 71.0M
Free Cash Flow -72.8M -65.5M -97.5M -98.6M -13.2M

Cash Flow Trend

Absci Key Financial Ratios

Valuation Ratios

Forward P/E -3.89
Price to Book 1.77
Price to Sales 73.12
PEG Ratio -3.89

Profitability Ratios

Profit Margin 0.00%
Operating Margin -2,351.91%
Return on Equity -48.98%
Return on Assets -27.53%

Financial Health

Current Ratio 5.72
Debt to Equity 4.49
Beta 2.07

Per Share Data

EPS (TTM) -$0.93
Book Value per Share $1.56
Revenue per Share $0.04

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
absi 352.1M - 1.77 -48.98% 0.00% 4.49
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Vera Therapeutics 1.4B -8.41 2.58 -39.49% 0.00% 10.18
Immunocore Holdings 1.6B -31.41 4.13 -5.86% -6.48% 114.67
Agios 1.9B 2.89 1.32 60.26% 1,798.26% 3.61

Financial data is updated regularly. All figures are in the company's reporting currency.